



Tecelra® Cell Therapy Treatment Centers

ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are qualified treatment centers (QTCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Tecelra®** (afamitresgene autoleucel; afami-cel) which is approved to treat **Synovial Sarcoma**.

For assistance with your member referral or for more information, contact ETS at clientservices@emergingtherapies.com or 877-445-4822.

▼ Denotes facilities that currently have cellular therapy rates in place with ETS.

State	City	Program Listing
California	Duarte	City of Hope
	Loma Linda	Loma Linda University Medical Center
	Stanford	Stanford Hospitals and Clinics ▼
Colorado	Aurora	University of Colorado Hospital
Florida	Jacksonville	Mayo Clinic ▼
	Tampa	H. Lee Moffitt Cancer Center ▼
	Miami	University of Miami Hospital
Illinois	Chicago	Northwestern Memorial Hospital
Maryland	Baltimore	University of Maryland Medical Center
Massachusetts	Boston	Dana-Farber Cancer Institute
		Massachusetts General Hospital
Michigan	Ann Arbor	University of Michigan Medical Center ▼
Minnesota	Rochester	Mayo Clinic ▼
Missouri	St. Louis	Barnes-Jewish Hospital ▼
New York	New York	Memorial Sloan-Kettering Cancer Center
North Carolina	Durham	Duke University Hospital
Ohio	Cleveland	Cleveland Clinic ▼
	Columbus	James Cancer Hospital
Oregon	Portland	Oregon Health & Science University
Pennsylvania	Philadelphia	Penn Medicine The Hospital at the University of Pennsylvania ▼
Tennessee	Nashville	Vanderbilt University Medical Center
Texas	Houston	MD Anderson Cancer Center